UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading_老虎社区_美港股上老虎

UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading

Seeking Alpha2022-01-21

While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).Analyst Eliana Merle said that with BioNTech shares ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Gabrielle_20
·2022-01-21
🥴
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1125663172?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-01-21 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125663172","market":"us","top_or_hot":-1,"title":"UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading","media":"Seeking Alpha","content":"<div>\n<p>While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).Analyst Eliana Merle said that with BioNTech shares ...</p>\n\n<a href=\"https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS cuts BioNTech price target by 43% saying pandemic trade premium is fading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-21 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).Analyst Eliana Merle said that with BioNTech shares ...</p>\n\n<a href=\"https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading","article_id":"1125663172","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125663172","pubTimestamp":1642774815,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"瑞银将生物技术公司的目标价格下调43%，称流行病贸易溢价正在消退","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9},"content_text":"While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).Analyst Eliana Merle said that with BioNTech shares down ~40% year to date, \"we think the recent move hints at a return to fundamentals after a highly volatile '21.\"Another big question for the company is what COVID-19 will be like once it becomes endemic and how that will impact the market for vaccine boosters, she notes.\"Key swing factors include: the durability of long-term immunity, novel variants, severity of reinfection, competitor COVID-19 vaccines and long-term pricing,\" Merle writes. \"We think the move to omicron specific vaccines is likely and will drive demand, though questions on whether further boosters beyond an omicron booster may follow,\" Merle writes.She notes that the company's pipeline is also too early \"to move the needle for shares in '22.\"","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":630887677,"gmtCreate":1642775889577,"gmtModify":1642775889738,"author":{"id":"3569531614182731","authorId":"3569531614182731","name":"Gabrielle_20","avatar":"https://static.tigerbbs.com/3687c03e4fcd937f9b3fa40fa7705b14","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569531614182731","authorIdStr":"3569531614182731"},"htmlText":"🥴","listText":"🥴","text":"🥴","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630887677","repostId":1125663172,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}